Payment overview · 2025
General Payments
$595.14
28 reported records · 11 companies
Healthcare provider profile · identity verified
Jennifer L White, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WESLEY CHAPEL, FL · NPI 1992094510
Verified facts
What the public records show
CMS Open Payments records show Jennifer L White, M.D. received $595.14 in general payments during 2025 across 28 reported records.
PFIZER INC. accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $172.53 | 29.0% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.87 | 28.9% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.73 | 10.7% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$45.24 | 7.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.26 | 4.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.54 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.52 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.84 | 3.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.59 | 3.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.98 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.04 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $595.14 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $172.53 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.45 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.56 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $89.96 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $82.57 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.73 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.42 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.60 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 115 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
96 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
94 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 984 | 384 |
| Losartan Potassium | Losartan Potassium | 643 | 236 |
| Levothyroxine Sodium | Levothyroxine Sodium | 623 | 217 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 508 | 198 |
| Famotidine | Famotidine | 482 | 220 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 194 |
| Pantoprazole Sodium | Pantoprazole Sodium | 378 | 159 |
| Omeprazole | Omeprazole | 364 | 143 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 122 |
| Lisinopril | Lisinopril | 314 | 123 |
| Montelukast Sodium | Montelukast Sodium | 287 | 108 |
| Gabapentin | Gabapentin | 275 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 92 |
| Alprazolam | Alprazolam | 240 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 238 | 123 |
| Trazodone Hcl | Trazodone Hcl | 229 | 89 |
| Metformin Hcl Er | Metformin Hcl | 218 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 87 |
| Sertraline Hcl | Sertraline Hcl | 199 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 90 |
| Meloxicam | Meloxicam | 195 | 102 |
| Furosemide | Furosemide | 185 | 71 |
| Simvastatin | Simvastatin | 178 | 60 |
| Tramadol Hcl | Tramadol Hcl | 175 | 62 |
| Carvedilol | Carvedilol | 170 | 52 |
| Ezetimibe | Ezetimibe | 164 | 67 |
| Finasteride | Finasteride | 161 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 155 | 78 |
| Methylprednisolone | Methylprednisolone | 154 | 135 |
| Metformin Hcl | Metformin Hcl | 146 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 48 |
| Alendronate Sodium | Alendronate Sodium | 117 | 50 |
| Glipizide Er | Glipizide | 116 | 37 |
| Eliquis | Apixaban | 115 | 46 |
| Januvia | Sitagliptin Phosphate | 115 | 42 |
| Potassium Chloride | Potassium Chloride | 115 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 29 |
| Allopurinol | Allopurinol | 108 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 37 |
| Azithromycin | Azithromycin | 105 | 96 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 102 | 45 |
| Ozempic | Semaglutide | 101 | 19 |
| Donepezil Hcl | Donepezil Hcl | 99 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 39 |
| Jardiance | Empagliflozin | 94 | 29 |
| Mounjaro | Tirzepatide | 94 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 26 |
| Lorazepam | Lorazepam | 84 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 35 |
| Synthroid | Levothyroxine Sodium | 80 | 29 |
| Myrbetriq | Mirabegron | 79 | 28 |
| Bupropion Xl | Bupropion Hcl | 78 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 33 |
| Temazepam | Temazepam | 75 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 73 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 60 |
| Xarelto | Rivaroxaban | 71 | 22 |
| Estradiol | Estradiol | 68 | 36 |
| Azelastine Hcl | Azelastine Hcl | 67 | 33 |
| Pregabalin | Pregabalin | 67 | 22 |
| Ondansetron Odt | Ondansetron | 66 | 40 |
| Prednisone | Prednisone | 66 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 23 |
| Meclizine Hcl | Meclizine Hcl | 60 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 23 |
| Clonazepam | Clonazepam | 55 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 29 |
| Valacyclovir | Valacyclovir Hcl | 53 | 32 |
| Glimepiride | Glimepiride | 52 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 13 |
| Tradjenta | Linagliptin | 50 | 19 |
| Cephalexin | Cephalexin | 49 | 42 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 41 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 18 |
| Buspirone Hcl | Buspirone Hcl | 46 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 20 |
| Propranolol Hcl | Propranolol Hcl | 44 | 18 |
| Primidone | Primidone | 41 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 22 |
| Memantine Hcl | Memantine Hcl | 38 | 16 |
| Sucralfate | Sucralfate | 38 | 28 |
| Atenolol | Atenolol | 37 | 17 |
| Nifedipine Er | Nifedipine | 37 | 16 |
| Spironolactone | Spironolactone | 35 | 15 |
| Baclofen | Baclofen | 34 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 14 |
| Celecoxib | Celecoxib | 30 | 14 |
| Clonidine Hcl | Clonidine Hcl | 30 | 12 |
| Diazepam | Diazepam | 30 | 13 |
| Midodrine Hcl | Midodrine Hcl | 30 | 14 |
| Valsartan | Valsartan | 30 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 23 |
| Telmisartan | Telmisartan | 29 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | 11 |
| Ketoconazole | Ketoconazole | 28 | 20 |
| Lidocaine | Lidocaine | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 25 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | 15 |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | 19 |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Linzess | Linaclotide | 22 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 15 |
| Nystatin | Nystatin | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $595.14 · 28 records | PFIZER INC. | CAPVAXIVE, ELIQUIS, GARDASIL 9, INTELLIS ADAPTIVESTIM, JARDIANCE, Korlym, MICRA, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SYNTHROID, TZIELD, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error